Background Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC)
defined by the lack of immunohistochemical expression of the estrogen and progesterone …

In contrast to endocrine-sensitive and human epidermal growth factor receptor 2 (HER2)–positive
breast cancer, novel agents capable of treating advanced triple-negative breast …

… Another aspect to consider is racial differences in response to statin treatment associated
with variations in the HMG-CoA-R gene. Two common HMG-CoA-R haplotypes, H2 and H7, …

Chlamydomonas reinhardtii is a unicellular green alga whose lineage diverged from land
plants over 1 billion years ago. It is a model system for studying chloroplast-based …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Purpose: To compare the clinical features, natural history, and outcomes for women with “triple-negative”
breast cancer with women with other types of breast cancer. Experimental …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard-of-…

Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …

Objectives : This study sought to evaluate the efficacy and safety of subcutaneous evolocumab
compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate …

Purpose To estimate the rate of pathologic complete response (pCR) to neoadjuvant
chemotherapy in BRCA1 mutation carriers according to chemotherapy regimen. Patients and …